

Preface

THE NF- κ B PATHWAY BROUGHT MAMMALIAN SIGNAL TRANSDUCTION into the modern era, allowing the analysis of cell signaling to become inclusive and holistic. Prior to its definition, biologists had focused on receptor-proximal events, largely through study of receptor tyrosine kinases and G-protein-coupled receptors or the study of isolated protein kinases. The gaping hole in our understanding at that point was the connection to the nucleus. It was clear that many of the physiological effects of receptor signaling were achieved by altering gene expression, but how signals were transduced from the plasma membrane to the nucleus was by-and-large a mystery. The elucidation of NF- κ B signaling in all of its molecular glory provided a new paradigm for understanding how receptor signaling can elicit transcriptional responses in mammalian cells. Even more importantly, NF- κ B helped transform the study of cell signaling from dealing with cultured cells to consideration of whole animal systems.

As David Baltimore points out in his introduction, NF- κ B was born rather innocently in a search for transcriptional regulators of the immunoglobulin locus. At the time, this effort was directed towards understanding the orchestrated changes in gene expression that take place during lymphocyte development. However, by following their noses, scientists in the Baltimore lab soon realized that the nuclear accumulation of the NF- κ B DNA binding proteins could be induced by a number of extracellular stimuli and set out to understand how this molecular connection was made. The discovery that NF- κ B exists in a latent form in the cytoplasm and translocates to the nucleus in response to various stimuli changed the way mammalian signal transduction was conceptualized.

What followed was a breathtaking explosion of research that uncovered pivotal roles for NF- κ B in a host of biological processes critical for normal physiology of animals and their ability to counter stress, disease, and infection. As Jules Hoffman discusses, NF- κ B emerged early in animal evolution as an important regulator of development and as a defense mechanism against invading pathogens, themes that have been embellished in vertebrate evolution. Although mammals no longer count on NF- κ B in the control of general development and morphogenesis, they use it to signal downstream of a host of receptors, many of which are members of extended gene families to control responses to stress, infection, and injury.

This collection includes reviews of the molecular mechanisms by which NF- κ B transcription factors are activated and exert their function in the nucleus, as well as reviews that summarize certain realms of biology that are particularly influenced by NF- κ B signaling. Ingrid Wertz and Vishva Dixit focus on the mechanisms whereby receptors that detect antigens, inflammatory cytokines, and foreign organisms utilize protein-protein interactions and the ubiquitin system to engage I κ B kinase (IKK) to initiate NF- κ B signaling. The structure of IKK complex components and the elaborate regulation of its protein kinase activity are described by Alain Israël in his contribution. Andrea Oeckinghaus and Sankar Ghosh summarize the process by which I κ Bs sequester NF- κ B in a latent state in the cytoplasm and how IKK action relieves this inhibition. Yinon Ben-Neriah and colleagues discuss the role of ubiquitination in the regulated degradation of the I κ Bs. The Rel-homology DNA binding domains of NF- κ B transcription factors are discussed in structural detail by Tom Huxford and Goury Ghosh. The various NF- κ B heterodimers have distinct target genes, as discussed by Ranjan Sen and Steve Smale, and can be altered in their transcription regulatory activities by post-translational modifications and association with co-factors, as discussed by

Fengyi Wan and Mike Lenardo. Chromatin structure further shapes the transcriptional output of NF- κ B dimers, as reviewed by Gioacchino Natoli. The overall biological output of NF- κ B signaling must be viewed from a systems biology perspective, as argued by Ellen O’Dea and Alex Hoffmann, whereas Steve Gerondakis and Uli Siebenlist recount the manifold ways in which NF- κ B signaling controls lymphocyte differentiation, activation, and function in vivo. Equally important is the regulation of innate immunity and inflammatory responses, as presented by both Toby Lawrence and Michael Karin. Inflammation can promote cancer development, and Michael Karin outlines the compelling evidence for the critical pathogenic role played by NF- κ B signaling in this process. Not surprisingly, cancers of many varieties accumulate genetic lesions that subvert NF- κ B signaling to protect against cell death and promote proliferation, offering many possible avenues for therapy, as discussed by Lou Staudt. Barbara and Christian Kaltschmidt remind us that without NF- κ B in our neurons, we would suffer learning disabilities and memory loss and would gain little from reading collections like this!

Twenty-four years after the discovery of mammalian NF- κ B and more than 25,000 publications later, there remain mysteries and challenges in the NF- κ B field. The contribution by Tao Lu and George Stark demonstrates that unbiased genetic screens continue to yield new regulators of NF- κ B, so it will be years before we have a complete parts list for this system and a full understanding of its working. Given the dysregulation of NF- κ B in inflammatory and autoimmune diseases, as well as in cancer, it is imperative that precise methods to manipulate NF- κ B are developed. This will be a challenge given the baroque regulation of the NF- κ B signaling system and its diverse biological functions, but one that can be met by building on the strong edifice of knowledge presented in this volume.

Finally, we wish to thank the Cold Spring Harbor Laboratory Press project manager, Mary Cozza, for her excellent support in pulling this book together, as well as Alex Hoffmann, whose NF- κ B wiring diagram formed the basis of the front cover illustration.

MICHAEL KARIN

University of California, San Diego

LOUIS M. STAUDT

National Cancer Institute

Index

A

- Act1 (NF- κ B activator 1), 256–257
- Activated B-cell-like (ABC) DLBCL
 - cancer therapies and, 158–159, 160
 - involvement in cancer development, 170–171
 - oncogenic activation of NF- κ B
 - activation of NF- κ B pathway, 140
 - biological consequences of NF- κ B signaling, 141
 - chronic ABC receptor signaling, 144–146
 - engagement of the CARD11 module, 141–143
 - genetic alterations deregulating NF- κ B in, 146–147
 - influence of NF- κ B signaling on, 141
 - oncogenic CARD11 mutations, 143–144
- Anhidrotic ectodermal dysplasia (EDA-ID), 59
- Ankyrin repeat domain (ARD), 40
- Aryl hydrocarbon receptor (AhR), 26–27
- Ataxia telangiectasia mutated (ATM), 135
- Azoxymethane (AOM), 172

B

- β -catenin, 27–28, 66, 67, 68, 69, 75, 172
- B-cell chronic lymphocytic leukemia, 170
- B-cells. *See* Lymphocyte development and function and NF- κ B
- Bcl3, 11, 42–43
- Binding activity. *See* Specification of DNA binding activity of NF- κ B complexes
- B lymphocytes. *See* Lymphocyte development and function and NF- κ B
- Bortezomib, 74–75, 159
- β -TrCp
 - I κ B recognition by, 68–69
 - interference, 159
 - regulation, 67–68

C

- CAC (colitis-associated cancer), 172–174
- Cactus, 224. *See also* Immune response of *Drosophila* and NF- κ B
- Cancer. *See* Inflammation and cancer link and NF- κ B; Oncogenic activation of NF- κ B

- CaP (prostrate cancer), 176–179
- CARD11/BCL10/MALT1 (CBM) signaling complex
 - engagement of in ABC DLBCL, 141–143
 - oncogenic mutations, 143–144, 146–147
 - relationship with marginal zone B-cell differentiation, 149
 - role in B-cell lymphoma, 170–171
 - targeting of specific cancer pathways and, 159–160
- CD40 system for noncanonical NF- κ B signaling, 90–91
- CD4 and DC9 thymocytes, 197–199
- CD79, 144–146
- Cdk9 (cyclin-dependent kinase 9), 28
- Chromatin organization and control of NF- κ B-dependent transcriptional responses
 - classes of regulated genes, 118–120
 - complexity of inflammatory transcriptional responses, 117–118
 - concluding remarks and future studies, 125
 - genetic dissection of chromatin remodeling events
 - absence of I κ B ξ , 121
 - chromatin remodeling, 120
 - regulatory layers, 120–121
 - steps in the gene activation process, 121
 - molecular bases of differential chromatin accessibility, 122–124
 - transcription factors' locating of relevant binding sites in the genome, 124–125
- Colitis-associated cancer (CAC), 172–174
- c-Rel, 7
 - de novo synthesis, 109
 - NF- κ B pathway in inflammation and, 185
 - post-translational modifications of Rel proteins, 24–25
 - selectivity of mechanisms used, 104–106
 - target gene selectivity, 102–104
- Cyclin-dependent kinase 9 (Cdk9), 28
- CYLD, 152, 153f, 154, 155–156

D

- Dasatinib, 160
- DEN (diethylnitrosamine), 174–176

- Deubiquitinases (DUBs), 69, 83–84
 Dextrane sulfate sodium (DSS), 172
 Diethylnitrosamine (DEN), 174–176
 Dimer generation regulation
 dimerization process, 129
 equilibrium states, 129–131
 stimulus-responsive alterations, 131, 132f
 DNA binding in NF- κ B. *See* Specification of
 DNA binding activity of NF- κ B
 complexes
 Dorsal-related immunity factor (DIF), 223–224.
 See also Immune response of *Drosophila*
 and NF- κ B
 DP thymocytes, 197–199
Drosophila. *See* Immune response of *Drosophila*
 and NF- κ B
 DSS (dextrane sulfate sodium), 172
- E**
- E3 ubiquitin ligase, 66–67
 EBV (Epstein-Barr virus), 148–149, 171
 EDA-ID (anhidrotic ectodermal dysplasia), 59
 ELKS protein, 60
 Epithelial cancers
 CYLD as a tumor suppressor, 155–156
 unconventional IKKs and, 156–158
 Epithelial cells, thymic, 202–204
 Epstein-Barr virus (EBV), 148–149, 171
- F**
- F-box protein (FBP), 66–67
 FBXL11, 259–260
 Forward genetics and regulators of NF- κ B
 approaches to study of NF- κ B
 cDNA library expression, 256–257
 chemical mutagenesis, 255–256
 insertional mutagenesis (*see* Insertional
 mutagenesis in forward genetics studies)
 concluding remarks and future studies, 260–262
 mammalian cells in tissue culture and, 253
 selection system to identify mutants, 253–254
- G**
- GABAergic interneurons, 243
 γ -aminobutyric acid (GABA), 240
 Ganciclovir (GCV), 254. *See also* Forward genetics
 and regulators of NF- κ B
 Germinal center B-cell-like (GCB) DLBCL
 involvement in cancer development, 170–171
 oncogenic activation of NF- κ B, 140, 141, 145,
 146–148, 159, 160
- Glia and NF- κ B in the nervous system, 247
 Glutamate, 240
- H**
- Hepatocellular carcinoma (HCC), 174–176
 Hodgkin lymphoma, 148–149
 Hodgkin Reed-Sternberg (HRS), 148
 Hsp70, 60
 Hsp90, 60, 158
 Hypothalamus and NF- κ B in the nervous system,
 244–246
- I**
- IKK kinase (IKK) complex, 7
 activation cascade in prostate cancer, 176–179
 activation of catalytic subunits, 52–54
 catalytic subunits, 51
 epithelial cancers and, 156–158
 function, 12
 IKK α and IKK β , 51
 IKK α and NF- κ B pathway in inflammation,
 187–189
 IKK β -based cancer therapies, 179–180
 IKK β inhibitors and NF- κ B link between
 inflammation and cancer, 172–174
 IKK β inhibitors and therapy of NF- κ B-driven
 cancers, 158–159
 IKK β inhibitors anti-inflammatory roles, 186
 mice knockout experiments, 60–61
 NEMO/IKK γ regulatory subunit
 canonical pathway and, 54
 function, 51–52, 54–55
 hypomorphic mutations results, 59
 interferon regulatory factor signaling
 pathways and, 57
 loss of function mutations results, 58–59
 polyubiquitination role, 57
 post-translational modifications, 57–58
 ubiquitin binding, 55–57
 vFLIP and, 54
 NF- κ B signaling module and
 catalytic subunit domain organization,
 43–44
 complex oligomerization, 45
 distinct activation pathways, 45
 emerging structure of NEMO/IKK γ , 45–46
 introduction to, 43
 NEMO/IKK γ domain organization,
 44–45
 physiological significance, 12, 13f
 probability of other components, 59–60
 regulation of binding activity and, 21–23

- I κ B proteins, 7
 - atypical protein Bcl3, 11
 - canonical signaling and, 9–10
 - characteristics of, 9
 - I κ B-dependent export and NF- κ B activation, 106–108
 - integrating signals that control I κ B
 - inflammatory signals and developmental signals cross talk, 136
 - ribotoxic stresses and inflammatory signals cross talk, 136
 - integrating signals that control NF- κ B synthesis and I κ B degradation, 137
 - NF- κ B signaling module and
 - classical sequence and structure, 40–41
 - I κ B α dynamics, 41–42
 - interactions with NF- κ B, 41
 - introduction to, 40
 - nonclassical proteins, 42
 - nuclear proteins, 42–43
 - precursor proteins p100 and p105, 10–11
 - regulation of binding activity and, 20–24
 - regulation of NF- κ B activity
 - process description, 131–133
 - signaling in response to cellular stresses, 135
 - signaling in response to developmental signals, 134–135
 - signaling in response to inflammatory signals, 133–134
 - signal responsiveness and, 9
 - ubiquitination and degradation
 - β -TrCp regulation, 67–68
 - concluding remarks and future studies, 75–76
 - control of p100 and p105, 71–72
 - degradation kinetics, 69–71
 - E3 ubiquitin ligase, 66–67
 - experiments characterizing, 65–66
 - recognition by β -TrCp, 68–69
 - role in termination of NF- κ B signaling, 72–74
 - subcellular location of, 72
 - therapeutic implications of degradation, 74–75
- I κ B ξ
 - absence in chromatin remodeling, 121
 - I κ B and, 42–43
- I- κ K- β activation and polyubiquitination, 84–85
- Il12b*, 104, 105
- IL1R1/TLR4, 88–89
- IL-1 signaling, 185, 255
- IMD (immuno-deficiency) pathway activation of NF- κ B
 - comments on, 232–233
 - intracytoplasmic cascade process, 231–232
 - kinetics of, 232
 - PGRP family and, 230–231
 - Pirk and, 232
 - TAK1 activation of the JNK branch, 232
 - Toll and, 224–225
- Immune response of *Drosophila* and NF- κ B
 - activation of NF- κ B by IMD pathway
 - comments on, 232–233
 - intracytoplasmic cascade process, 231–232
 - kinetics of, 232
 - PGRP family and, 230–231
 - Pirk and, 232
 - TAK1 activation of the JNK branch, 232
 - activation of NF- κ B via the Toll signaling cascade
 - fungal or yeast glucans and, 227
 - interaction with death domains, 227–228
 - kinetics of, 228–229
 - PGRP family and, 225–227
 - response to microbial infections, 229–230
 - Cactus and Relish, 224
 - concluding remarks and future studies, 233–234
 - dorsal and DIF, 223–224
 - Toll and Imd, 224–225
- Immune system
 - of *Drosophila* (*see* Immune response of *Drosophila* and NF- κ B)
 - roles of NF- κ B pathway in (*see* Lymphocyte development and function and NF- κ B)
- Immunoreceptor tyrosine-based activation motifs (ITAMs), 91–92
- Incontinentia pigmenti (IP), 58–59
- Inflammation and cancer link and NF- κ B
 - colitis-associated cancer, 172–174
 - hepatocellular carcinoma, 174–176
 - IKK activation cascade in prostate cancer, 176–179
 - IKK β -based therapies, 179
 - lymphoid malignancies, 170–172
 - recognition of a NF- κ B role in cancer, 169–170
 - targeted therapy potential, 179–180
- Inflammation and the NF- κ B pathway
 - activation of NF- κ B in inflammation, 183–185
 - alternative pathway
 - IKK α and, 187–189
 - lymphoid organogenesis role, 189
 - RelB monomer and, 188
 - canonical pathway
 - anti-inflammatory roles of IKK β , 186
 - apoptosis and, 187
 - chronic inflammatory diseases associated with, 185t
 - gene knockout studies, 186–187
 - RelA- or cRel-containing complexes, 185

- Inflammation and the NF- κ B pathway (*continued*)
 canonical pathway (*continued*)
 tissue-specific role, 185–186
 TNF α and IL-1 signaling, 185
 summary, 189–190
- Insertional mutagenesis in forward genetics studies
 information about p65 and TAB3 from
 retroviral, 257, 258f
 transposon-mediated, to discover short RIP,
 257, 259
 VBIM technique to discover
 FBXL11, 259–260
- Interferon regulatory factor (IRF) signaling
 pathways, 57
- IP (incontinentia pigmenti), 58–59
- ITAMs (immunoreceptor tyrosine-based activation
 motifs), 91–92
- K**
- Kruppel-associated box (KRAB), 259
- Kupffer cells, 174–176
- L**
- Lamina propria macrophages, 172
- Learning and NF- κ B, 239–240, 242–244. *See also*
 Nervous system and NF- κ B
- Lipopolysaccharide (LPS)
 IKK complex and, 45, 53, 55
 IL1R1/TLR4 and, 88–89
 induction of NF- κ B, 2
 NF- κ B induction by, 109, 120–121, 134
- Liver apoptosis, 60
- Lymphocyte development and function and NF- κ B
 B-cell activation and, 205–207
 B-cell division and, 207–208
 cell-autonomous roles of NF- κ B
 DP and SP thymocytes, 197–199
 early lymphocyte progenitors, 193–196
 immature (bone marrow) B cells and negative
 selection, 197
 mature and marginal zone B cells, 200–202
 NF- κ B in thymic epithelial cells, 202–204
 nonconventional T cells, 199–200
 pre-antigen receptor expression and, 196
 small (late) pre-B cells, 196–197
 concluding remarks and future studies, 214
 control of activated B-cell survival, 208–209
 effector T-cell differentiation and, 213–214
 isotype switching, 209–210
 stromal cells and establishment of secondary
 lymphoid organs, 204–205
 T-cell activation and, 210
 T-cell proliferation and, 210–211
 T-cell survival and, 212–213
- Lymphocyte-predominant Hodgkin lymphoma, 149
- Lymphoma and NF- κ B, 140, 148–151, 170–172
- M**
- MALT (mucosa-associated lymphoid tissue),
 149–151, 160
- Marginal zone B cells (MZB), 149, 200–202
- Medullary thymic epithelial cells (mTECs), 203–204
- Memory and NF- κ B, 242–244. *See also* Nervous
 system and NF- κ B
- Mi2/Nurd, 120
- MLN4924, 159
- mTECs (medullary thymic epithelial cells), 203–204
- Mucosa-associated lymphoid tissue (MALT),
 149–151, 160
- Multiple myeloma (MM), 74–75, 152–155, 171
- MZB (marginal zone B cells), 149, 200–202
- N**
- NEDD8, 159
- NEMO/IKK γ regulatory subunit
 canonical pathway and, 54
 definition of IKK and, 128
 domain organization, 44–46
 emerging structure of, 45–46
 function, 51–52, 54–55
 hypomorphic mutations results, 59
 interferon regulatory factor signaling pathways
 and, 57
 loss of function mutations results, 58–59
 polyubiquitination role, 57
 post-translational modifications, 57–58
 ubiquitin binding, 55–57
 vFLIP and, 54
- Nervous system and NF- κ B
 biochemical/cellular concept of memory, 240
 defining learning, 239–240
 glia, 247
 hypothalamus, 244–246
 learning and memory and, 242–244
 neural stem cells, 248
 neurons and, 240, 242
 neuroprotection, 246–247
 NF- κ B's role in the cellular context of, 241f
 pain and, 247–248
- Neural stem cells, 248
- NF- κ B
 cellular response to stimuli (*see* Selectivity of
 the NF- κ B response)
 dimers' physiological role, 9

- discovery of, 1–2
 - I κ B proteins (*see* I κ B proteins)
 - IKK complex (*see* I κ B kinase (IKK) complex)
 - immune response of *Drosophila* and (*see* Immune response of *Drosophila* and NF- κ B)
 - inhibition of I κ B (*see* I κ B proteins, ubiquitination and degradation)
 - involvement in cancer development (*see* Inflammation and cancer link and NF- κ B; Oncogenic activation of NF- κ B)
 - lymphocytes and (*see* Lymphocyte development and function and NF- κ B)
 - post-translational modifications, 12–14
 - protein binding activity (*see* Specification of DNA binding activity of NF- κ B complexes)
 - signaling and (*see* Regulatory logic of the NF- κ B signaling system; Signaling by ubiquitination; Signaling module)
 - stimuli and κ B-dependent target genes, 6–7
 - termination of the NF- κ B response, 14–15
 - transcriptional control (*see* Specification of DNA binding activity of NF- κ B complexes)
 - transcriptional responses (*see* Chromatin organization and control of NF- κ B-dependent transcriptional responses)
 - transcription factor family, 7–9
 - NF- κ B essential modulator. *See* NEMO/IKK γ regulatory subunit
 - NF- κ B inducing kinase (NIK), 128, 160–161, 171
 - NOD2, 93–95
 - Nucleotide-binding domain leucine-rich repeat (NLR), 93
 - Nucleotide-binding oligomerization domain (NOD), 93
- O**
- Oncogenic activation of NF- κ B
 - ABC DLBCL
 - activation of NF- κ B pathway, 140
 - biological consequences of NF- κ B signaling, 141
 - chronic ABC receptor signaling, 144–146
 - engagement of the CARD11 module, 141–143
 - genetic alterations deregulating NF- κ B in, 146–147
 - influence of NF- κ B signaling on, 141
 - oncogenic CARD11 mutations, 143–144
 - epithelial cancers
 - CYLD as a tumor suppressor, 155–156
 - unconventional IKKs and, 156–158
 - GCB DLBCL, 147–148
 - Hodgkin lymphoma, 148–149
 - MALT lymphoma, 149–151
 - multiple myeloma, 152–155
 - NF- κ B's role in the initiation and promotion of cancer, 139–140
 - primary mediastinal B-cell lymphoma, 140, 148
 - therapy of NF- κ B-driven cancers
 - β TrCP interference, 159
 - chronic ABC receptor signaling, 160
 - IKK β inhibitors, 158–159
 - NIK targeting, 160–161
 - proteasome inhibitor bortezomib, 159
 - strategies targeting specific upstream pathways, 159–161
- P**
- p100, 23, 42, 71–72
 - p100/52 (NF- κ B2), 7, 10–11
 - p105, 23, 42, 71–72
 - p105/p50, 7, 10–11
 - p50 and p52, 106
 - p50/p65 heterodimers, 7
 - p65 (RelA), 7, 13–14, 15, 242
 - Pain and NF- κ B in the nervous system, 247–248
 - Peptidoglycan recognition proteins (PGRPs), 225–227, 230–231
 - Pirk, 232
 - Primary mediastinal B-cell lymphoma (PMBL), 140, 148
 - Prostate cancer (CaP), 176–179
- R**
- Receptor-interacting protein kinase 1 (RIP1), 259
 - Regulatory logic of the NF- κ B signaling system
 - concluding remarks and future studies, 137
 - integrating signals that control I κ B
 - inflammatory signals and developmental signals cross talk, 136
 - ribotoxic stresses and inflammatory signals cross talk, 136
 - integrating signals that control NF- κ B synthesis and I κ B degradation, 137
 - molecular components of the system, 127–128
 - regulation of activity via I κ B
 - process description, 131–133
 - signaling in response to cellular stresses, 135
 - signaling in response to developmental signals, 134–135
 - signaling in response to inflammatory signals, 133–134

- Regulatory logic of the NF- κ B signaling system (*continued*)
- regulation of dimer generation
 - dimerization process, 129
 - equilibrium states, 129–131
 - stimulus-responsive alterations, 131, 132f
 - regulatory mechanisms, 128–129
- RelA (p65), 7
- de novo c-Rel synthesis and, 109
 - NF- κ B pathway in inflammation and, 185
 - nuclear degradation of, 108
 - post-translational modifications of
 - acetylation, 26
 - c-Rel, 24–25
 - phosphorylation of p65, 24
 - RelB monomer, 25–26
 - selectivity of mechanisms used, 104–106
 - subunit-associating proteins, 20, 26–28
 - target gene selectivity, 102–104
- RelB, 7, 188
- Rel homology domain (RHD), 20
- Rel homology region (RHR), 36–37
- Relish, 224. *See also* Immune response of *Drosophila* and NF- κ B
- RIG-1, 93–95
- RIG-1-like receptors (RLR), 93
- RIP1 (receptor-interacting protein kinase 1), 259
- RPS3, 29–30
- S**
- S276 phosphorylation, 104–105
- Selectivity of the NF- κ B response
- complexity and diversity of NF- κ B function and regulation, 101–102
 - concluding remarks and future studies, 113
 - duration of activation, 107f
 - control by secondary stimulation, 109
 - de novo c-Rel synthesis, 109
 - I κ B-dependent export, 106–108
 - nuclear degradation of RelA, 108
 - mechanisms of target genes
 - by c-Rel and RelA, 104–106
 - by p50 and p52, 106
 - patterns of gene expression
 - duration of gene transcription, 112
 - lineage-specific marking, 110
 - post-transcriptional regulation of target genes, 112–113
 - rate of gene induction, 111–112
 - stimulus-specific marking, 110–111
 - target gene selectivity of distinct dimers, 102–104
- Signaling by ubiquitination
- concluding remarks and future studies, 95–96
 - introduction to NF- κ B signaling, 81–82
 - ubiquitin/proteasome system
 - CD40 system for noncanonical signaling, 90–91
 - components and pathways, 82t, 85–86
 - IL1R1/TLR4, 88–89
 - inactivation of NF- κ B signaling, 85
 - NF- κ B activation by intracellular stimuli, 93–95
 - polyubiquitination and I- κ B activation, 84–85
 - system description, 82–84
 - TCR antigen receptor, 91–93
 - TNFR1, 86–88
- Signaling module
- dimerization, 37–38
- I κ B
- classical sequence and structure, 40–41
 - I κ B α dynamics, 41–42
 - interactions with NF- κ B, 41
 - introduction to, 40
 - nonclassical proteins, 42
 - nuclear proteins, 42–43
 - proteins ubiquitination and degradation
 - role in pathway, 72–74
- IKK
- catalytic subunit domain organization, 43–44
 - complex oligomerization, 45
 - distinct activation pathways, 45
 - emerging structure of NEMO/IKK γ , 45–46
 - introduction to, 43
 - NEMO/IKK γ domain organization, 44–45
 - introduction to, 35–36
 - mechanisms that mediate signaling cross talk (*see* Regulatory logic of the NF- κ B signaling system)
- NF- κ B
- dimerization, 37–38
 - introduction to, 35–36
 - recognition of κ B DNA, 38–40
 - Rel homology region structure, 36–37
 - recognition of κ B DNA, 38–40
 - Rel homology region structure, 36–37
- Specification of DNA binding activity of NF- κ B complexes
- concluding remarks and future studies, 30–31
 - function, 20
 - I κ B proteins and regulation of binding activity, 20–24
 - integral non-Rel subunits in NF- κ B complexes, 28–30

post-translational modifications of Rel proteins,
24–26
regulatory effects of Rel-associating proteins,
27–28
Rel subunit-associating proteins, 20, 26–28
SP thymocytes, 197–199
STAT3 transcription factor
forward genetics and NF- κ B and, 261
NF- κ B role in inflammation and cancer and,
172–174, 175f, 176–178, 179
NF- κ B signaling in ABC DLBCL and, 141
Stromal cells and establishment of secondary
lymphoid organs, 204–205

T

TAD (transcription activation domain), 20
TAK1 activation of the JNK branch, 232
T-cells. *See* Lymphocyte development and function
and NF- κ B
TCR antigen receptor, 91–93
Thymocytes, DP and SP, 197–199
TIR domains, 227
T lymphocytes. *See* Lymphocyte development and
function and NF- κ B
TNF α , 185
TNFR1, 86–88
TNF receptor associated protein with a death domain
(TRADD), 86–87

Toll signaling cascade activation
fungal or yeast glucans and, 227
immune response of *Drosophila* and NF- κ B,
224–225
interaction with death domains, 227–228
kinetics of, 228–229
peptidoglycan recognition proteins,
225–227
response to microbial infections,
229–230
TRAF2, 90–91
TRAMP mouse, 176–177
Transcription activation domain (TAD), 20

U

Ubiquitin/proteasome system (UPS), 82–84.
See also Signaling by ubiquitination

V

Validation-based insertional mutagenesis
(VBIM), 259
vFLIP, 54

Z

Zeocin (Zeo), 254. *See also* Forward genetics and
regulators of NF- κ B